Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075251 | 0.78 | CHRM1 (0.42) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL16803640 | 0.78 | CHRNB2 (0.33) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL19669891 | 0.77 | CHRM1 (0.41) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL19668991 | 0.77 | CHRM1 (0.43) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL26073790 | 0.74 | CYP2D6 (0.42) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL18909572 | 0.73 | — | — | |
| SCHEMBL18136238 | 0.73 | — | — | |
| SCHEMBL1895672 | 0.73 | — | — | |
| SCHEMBL21937236 | 0.73 | — | — | |
| SCHEMBL26075132 | 0.72 | CHRM1 (0.37) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113490497-B | Pharmaceutical composition for treating acute myeloid leukemia comprising FLT3 inhibitor and hypomethylating agent | 韩美药品株式会社 | 2025-04-04 | — | — | CN | disclosed |
| CN-114650823-A | Pharmaceutical composition comprising FLT3 inhibitor and chemotherapeutic agent for the treatment of acute myeloid leukemia | 韩美药品株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20070265260-A1 | Quinazoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | CHRM1 4880/4885CHRM2 4862/4885CHRM4 4858/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | CHRM1 4880/4885CHRM2 4884/4885CHRM4 4858/4885 |
| US-20070265260-A1 | Quinazoline derivatives | TYK2, ROR1, JAK1 | CHRM1 3699/4885CHRM2 4672/4885CHRM4 4723/4885 |
| US-20080200433-A1 | Molecular Chaperone Function Regulator | HSPBP1, HSF1, HSPH1 | CHRM1 4702/4885CHRM2 4832/4885CHRM4 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.